Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Navepegritide: First Approval.

Drugs·2026
Same author

Pixavir Marboxil: First Approval.

Drugs·2026
Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Correction: Donanemab: First Approval.

Drugs·2024
Same author

Donanemab: First Approval.

Drugs·2024
Same author

Sotatercept: First Approval.

Drugs·2024

相关实验视频

Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

阿瓦辛卡普塔德·佩戈尔:第一次获得批准

Connie Kang1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 9, 2023
PubMed
概括

补充C5抑制剂Avacincaptad pegol现在已被批准用于治疗与年龄相关的黄斑变性二次性地理缩. 这标志着对这种晚期眼部疾病的治疗方法的开发取得了重要里程碑.

科学领域:

  • 眼科医生 眼科 眼科
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 与年龄相关的黄斑变性 (AMD) 二次的地理缩 (GA) 是不可逆转的视力丧失的主要原因.
  • 目前对GA的治疗选择有限,这凸显了需要有效的治疗干预措施的需要.
  • 补体系统调节失调,特别是涉及补体C5,与GA的发病有关.

研究的目的:

  • 要总结avacincaptad pegol的主要发展里程碑.
  • 要突出导致最近批准avacincaptad pegol用于AMD次要的GA的旅程.
  • 为提供avacincaptad pegol作为一种新型治疗剂的概述.

主要方法:

  • 阿瓦辛卡普塔德醇是一种新型补充C5抑制剂.
  • 开发涉及临床前研究和广泛的临床试验.
  • 为了获得市场批准,进行了监管提交和审查.

主要成果:

  • 在临床试验中,Avacincaptad pegol在减缓GA进展方面表现出有效性.
  • 药物的安全概况是通过严格的测试来确定的.
  • 开发工作的高潮导致监管部门的批准.

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

4.6K

相关实验视频

Last Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

4.6K

结论:

  • 阿瓦辛卡普塔德皮戈尔 (IZERVAYTM) 代表了治疗与年龄相关的黄斑变性继发的地理缩的重大进展.
  • 这项批准为患有这种衰弱状况的患者提供了新的治疗选择.
  • 成功的开发强调了补充C5抑制在管理AMD进展方面的潜力.